Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > DCs and NK cells as the enhancer of OVs

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jan 12, 2023 4:02pm

263 Views

Post# 35219490

DCs and NK cells as the enhancer of OVs

January 10, 2023 - "... efforts are being undertaken to prevent the immunosuppression that is linked with tumors. Anti-cancer treatment based on oncolytic viruses is one of the most fascinating therapeutic techniques for addressing such challenges (oncotherapy). OVs selectively target and destroy cancer cells through direct oncolysis and antitumor immunity (115).

Immunosuppression inside the tumor microenvironment (TME) provides an environment that is susceptible to infection and is permissive to viral multiplication, in the end, this leads to death of cancer cells. Upon OV-induced immunogenic cancer cell death and the subsequent "danger" signals, there is an increase in APC and lymphocyte infiltration in the TME.

This rise in APC and lymphocyte infiltration leads to the stimulation of nonspecific and specific anti-tumor response, reducing the risk of cancer recurrence over the long term (116). OVs are also responsible for the activation of additional immune responses, which serve to counterbalance the decrease in the presentation of tumor antigens and to boost the interaction of APCs with T cells that are specific to the tumor ..."

https://www.frontiersin.org/articles/10.3389/fimmu.2022.950079/full

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec